Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Currently Amended) A compound of Formula (I):



(I)

or a salt or solvate thereof, wherein:

one of R^1 and R^2 is H and the other represents – $NHCONHR^4$,

wherein R^4 represents

a phenyl or naphthyl group [[(]]which may be optionally substituted by one or more substituents independently selected from -C_{1-6} alkyl, -C_{1-6} haloalkyl, ~~$-CH_2CH_2CH_2-$~~, halogen, C_{1-6} alkoxy, C_{1-6} haloalkoxy, OH, $NO_{2[(]}$)]],

C_{3-7} cycloalkyl, indanyl, or

R^4 together with the NH to which it is bonded forms a morpholino group; and

R^3 is H or NHR^5

wherein R^5 is

H, -quinolinyl or –isoquinolinyl,

-$(CONH)_p$ phenyl [[(]]wherein p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from

halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -morpholino, -SO_2NH_2, and methyl substituted benzothiazole ~~(substituted by methyl))~~.

~~or a salt, solvate, or physiologically functional derivative thereof.~~

2. (Currently Amended) A compound according to claim 1 wherein R^4 represents C_{3-7} cycloalkyl, indanyl, or a phenyl group ~~(which~~ wherein said phenyl may be optionally substituted by one or more substituents selected from –C_{1-6} haloalkyl, ~~-$CH_2CH_2CH_2$-,~~ and halogen~~) or C_{3-7} cycloalkyl~~.

3. (Currently Amended) A compound according to claim[[s]] 1 [[– 2]] wherein R^3 is H or –NH R^5 wherein R^5 is H, quinolinyl, or -$(CONH)_p$ phenyl [[(]]wherein p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, -C_{1-6} haloalkyl –morpholino, -SO_2NH_2, and methyl substituted benzothiazole~~, (substituted by methyl))~~.

4. (Currently Amended) A compound according to claim[[s]] 1 [[– 3]] of formula (1a)



(1a)

wherein one of R^6 and R^7 is H and the other represents -$NHCONHR^9$;

R^9 represents C_{3-7} cycloalkyl, indanyl, or a phenyl group ~~(which~~ wherein said phenyl may be optionally substituted by one or more substituents independently selected from -C_{1-6} haloalkyl, ~~$-CH_2CH_2CH_2-$~~, and halogen~~)or C_{3-7} cycloalkyl~~;

R^8 is H or NHR^{10};

R^{10} is H, quinolinyl, or -(CONH)p phenyl [[(]]where p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, -C_{1-6} haloalkyl, -morpholino, -SO_2NH_2, and methyl substituted benzothiazole ~~(substituted by methyl))~~.

5. (Currently Amended) A compound according to claim 4 wherein $NHCONHR^9$ represents



6. (Currently Amended) A compound according to claim 4 [[and 5]] where in R^{10} is H,











7. (Currently Amended) A compound as claimed in claim 1 [[- 6,]] selected from the group consisting of:

1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-(3-isoquinolin-5-ylphenyl)urea;

1-Cyclohexyl-3-(3-isoquinolin-5-ylphenyl)urea;

1-[3-(1-Amino-isoquinolin-5-yl)-phenyl]-3-(2-fluoro-5-trifluoromethyl-phenyl)-urea ;

1-(2-fluoro-5-trifluoromethyl-phenyl)-3-(5-{3-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-isoquinolin-1-yl)-urea;

1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-{3-[1-(quinolin-6-ylamino)-isoquinolin-5-yl]-phenyl}-urea;

1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-(4-{1-[4-(6-methyl-benzothiazol-2-yl)-phenylamino]-isoquinolin-5-yl}-phenyl)-urea;

1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-(3-{1-[4-(6-methyl-benzothiazol-2-yl)-phenylamino]-isoquinolin-5-yl}-phenyl)-urea;

1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-(4-isoquinolin-5-ylphenyl)urea;

1-Indan-5-yl-3-(3-isoquinolin-5-yl-phenyl)-urea;

1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-{3-[1-(4-morpholin-4-yl-phenylamino)-isoquinolin-5-yl]-phenyl}-urea; and

3-{5-[3-(3-Cyclohexyl-ureido)-phenyl]-isoquinolin-1-ylamino}-benzenesulfonamide;

or a salt[[,]] or solvate~~, or physiologically functional derivative~~ thereof.

8. (Currently Amended) A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in ~~any one of~~ claim[[s]] 1 [[- 7]], or a salt[[,]] or solvate~~, or a physiologically functional~~

~~derivative~~ thereof and one or more of pharmaceutically acceptable carriers, diluents, and excipients.

9. (Original) A pharmaceutical composition according to claim 8 further comprising an agent to inhibit growth factor receptor function

10. (Cancelled)

11. (Currently Amended) A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate TIE-2, Eph B4, and VEGFR-2 activity, comprising administering to said mammal a compound according to claim[[s]] 1 [[- 7]] or a salt[[,]] or solvate ~~or a physiologically functional derivative~~ thereof.

12. (Cancelled)

13. (Currently Amended) A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate TIE-2, Eph B4, and VEGFR-2 activity, comprising: administering to said mammal (i) a compound according to claim[[s]] 1 [[- 7]], or a salt[[,]] or solvate ~~or physiologically functional derivative~~ thereof and (ii) an agent to inhibit growth factor receptor function.

14. (Cancelled)

15. (Currently Amended) A method of treating a disorder in a mammal, said disorder being_characterized by inappropriate angiogenesis, comprising administering to said mammal a compound according to claim[[s]] 1 [[- 7]], or a salt[[,]] or solvate ~~or physiologically functional derivative~~ thereof.

16. (Cancelled)